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ABSTRACT
Objective: The present work aimed at developing novel hybrid molecules for targeting the prostate 
cancer. It is observed that two human shock proteins Hsp70 and Hsp90 are over-expressed in prostate 
cancer making them one of the important drug targets. We have designed and developed twelve new 
hybrid molecules 6a-j for targeting these proteins. 
Methods: The designed molecules were prepared following a four step reaction protocol and charac-
terized on the basis of proton NMR and Mass spectrometry. These were subjected to in vitro studies by 
means of Oncotest and CCK-8 assays with two cell lines DU145 and 22Rv1. The selected molecules 6b 
and 6i were subjected to molecular docking and then for SPR based affinity assay.
Results: Compounds 6b and 6i were found to be highly active anticancer compounds comparable to 
standard drug enzalutamide. They have significant IC50 and high dock score for the Hsp70 and Hsp90. 
These compounds are selective and have good binding affinity for the Hsp70 due to high Kd. 
Conclusion: Compound 6b and 6i can serve as lead molecules for the development of antiprostate cancer 
drugs with Hsp70 as target.
Keywords: Hybrid; DU145; 22Rv1; SPR; Molecular docking.
RESUMEN
Objetivo: El presente trabajo tuvo como objetivo desarrollar nuevas moléculas híbridas para atacar el 
cáncer de próstata. Se observa que dos proteínas de choque humano, Hsp70 y Hsp90, se sobreexpresan 
en el cáncer de próstata, lo que las convierte en uno de los objetivos farmacológicos importantes. Hemos 
diseñado y desarrollado doce nuevas moléculas híbridas 6a-j para dirigir estas proteínas.
Métodos: Las moléculas diseñadas se prepararon siguiendo un protocolo de reacción de cuatro etapas 
y se caracterizaron sobre la base de RMN de protón y espectrometría de masas. Estos se sometieron a 
estudios in vitro por medio de ensayos Oncotest y CCK-8 con dos líneas celulares DU145 y 22Rv1. Las 
moléculas seleccionadas 6b y 6i se sometieron a acoplamiento molecular y luego a ensayo de afinidad 
basado en SPR.
Resultados: Se descubrió que los Compuestos 6b y 6i son compuestos anticancerígenos muy activos 
comparables al fármaco estándar enzalutamida. Tienen un IC50 significativo y una puntuación alta para 
el muelle de Hsp70 y Hsp90. Estos compuestos son selectivos y tienen una buena afinidad de unión por 
la Hsp70 debido a la alta Kd.
Conclusión: Los compuestos 6b y 6i pueden servir como moléculas principales para el desarrollo de 
fármacos antiprostáticos contra el cáncer con Hsp70 como objetivo.
Palabras clave: Híbrido; DU145; 22Rv1; SPR; acoplamiento molecular.
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INTRODUCTION
The heat shock proteins (Hsp) are induced in response to 
heat shock and other conditions such as chemical or physi-
cal stress conditions;these are encoded by the Hsp 27, 28, 40, 
70, 90 and 110 genes. These proteins possess the property of 
modifying other proteins, their functions and these interact 
to alter their normal functioning. They are highly efficient 
in synthesis of proteins in response to stress and have high-
ly efficient stabilisation effect thus maintaining the normal 
homeostasis by transcriptional activation, mRNA stabilisa-
tion and translation.1 Several studies have proved the role 
of Hsp70 and 90 in various biochemical and physiological 
process such as regulation of apoptosis via the apoptotic 
pathway, regulation for release and transport of mitochon-
drial cytochrome c, regulating the tumour necrosis factor 
(TNF) and its related apoptoticmoieties to respective recep-
tors.2 Hsp 70 and 90 are highly expressed in cancer that are 
drug resistant and are often observed in patients suffering 
from drug resistance to chemotherapeutic agents.3 Thus, 
these proteins have become logical and popular targets 
fordevelopment of anticancer agents. On this front very 
few drugs are available with Geldanamycin, Macbecin 
and Radicicolas only compounds available for inhibiting 
the Hsp90. Whereas, Apoptozole, dibenzyladenosine ana-
logues, Pifithrin, several pyrimidine analogues and flavo-
noids are found to inhibit Hsp70, but all these compounds 
are under investigation or in clinical phase.4 It has been well 
observed that overexpression of these heat shock proteins 
is one of the factors in progression of prostate cancer. Thus 
development of compounds that can inhibit these proteins 
could possibly lead to control over prostatic adenocarcino-
ma.5,6 This situation inspired us for development of some 
newer derivatives as inhibitors of Hsp70 and Hsp90 for 
treatment of prostate cancer. 
Figure 1: Anticancer drugs with hybrid nature and possess common three pharmacophore features as cyclic aliphatic group with substi-
tution, fused aromatic nucleus and the aryl substitutions generally acting as linker. 
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Several anticancer compounds are reported to have inhib-
itory activity towards the Hsp90 and Hsp70. On analysing 
these compounds it was found that these molecules have 
several common structural features and belongs to the ‘nib’ 
class of drugs. Compounds such as Bosutinib, Gefitinib, 
Ponatinib, Imatinib, Ceitinib, Afitinib and Ibrutinib have 
inhibitory action on the Hsp90 and 70.7-10 It was observed 
that these compounds have several common structural 
features such as fused ring structures or have an aliphat-
ic cyclic moiety with heteroatom and substituted aryl ring 
(fig.1). Along with these structural features it was observed 
that these compounds are hybrid in nature, formed from 
two or more biologically active chemical moieties. Benzox-
azole are reported to possess antitumor activity and can 
be synthesised by various routes, similarly piperidine is 
also reported to have anticancer activity.11-13 Based on these 
observations we designed novel hybrid molecules of ben-
zoxazole and piperidine with structural features similar to 
the cancer therapeutic agents. Benzoxazole was linked with 
substituted piperidine to yieldtwelve derivatives with dif-
ferent substitutions on the aryl ring (Scheme 1).
Scheme 1. Reagents and conditions for the synthesis of 6a-l: a) Dimethyl formamide (DMF), Potassium carbonate (K2CO3), room tem-
perature, 6 h; b) Sodium methoxide (CH3Na), Methanol, reflux, 12 h; c) Potassium Iodide (KI), Tetrahydrofuran (THF), Trifluroacetic 
acid, DCM, room temperature, 7 h; d) K2CO3, DMF, 4 h. 
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MATERIAL AND METHODS
Chemicals and solvents for this work were obtained from 
Alfa Aeser, UK and Sigma Aldrich, USA unless otherwise 
mentioned. Thiele’s tube melting-point apparatus was 
used to determine the melting points (mp) for all the com-
pounds within open capillaries and was recorded with-
out corrections. Infrared (IR) spectra were developed and 
created on JASCO FT/IR-4000 spectrophotometer (Jasco, 
USA) with KBr pellets used for compounds. Proton NMR 
(1H) spectra were recorded on a Bruker Advance-II 400 
Spectrometer on 400 MHz using tetramethylsilane (TMS) 
as internal standard. Chemical shift values for the synthetic 
derivatives were recorded as δ (parts per million), coupling 
constant value Jwas measured in hertz (Hz). The peaks are 
presented as s = singlet, d = doublet, t = triplet, dd = dou-
ble doublet, m = multiplet. In similar way 13C NMR were 
recorded. Thin Layer Chromatographic (TLC) method was 
used to determine the purity of compounds and progress 
of reaction using Merck, silica gel, HF254–361, type 60, 0.25 
mm. Electron Spray Ionisation Mass Spectrometry (ESI-
MS) were recorded on Waters HPLC system with Q-Time 
of Flight LC-MS spectrometry (Waters-Micromass LC-MS, 
US). 
Chemistry
The title compounds N-substituted benzyl-1-(6-methoxy-
benzo[d]oxazol-2-yl)-N-methylpiperidin-4-amine6a-l were 
obtained starting from benzoxazole in four step synthetic 
procedure, these procedures are discussed below as fol-
lows; 
Synthesis of tert-butyl 1-(6-chlorobenzo[d]oxazol-2-yl)piperi-
din-4-yl(methyl)carbamate3
A mixture of 2,6-dichlorobenzo[d]oxazole1 (1.0 mmol) and 
tert-butyl methyl(piperidin-4-yl)carbamate 2 (1.0 mmol) 
were stirred in DMF (5 mL) in presence of potassium car-
bonate for about 6 hours at room temperature, completion 
of reaction was monitored on TLC. The resulting com-
pound tert-butyl 1-(6-chlorobenzo[d]oxazol-2-yl)piperi-
din-4-yl(methyl) carbamate3 was isolated as off white ppt 
in 77% yield. Mp: 230-232 ºC; 1H-NMR (CDCl3): δ 1.49 (s, 
9H, Boc-CH3), 1.60 (m, 2H, Piperidine-H), 1.89 (m, 2H, Pip-
eridine-H), 2.3 (m, 2H, Piperidine-H), 2.5 (m, 2H, Piperi-
dine-H), 2.9 (s, 3H, N-CH3), 3.72 (m, 2H, methylene-H), 7.20 
(m, 1H, Ar-H), 7.85 (m, 1H, Ar-H); Anal. Calcd for C18H24Cl-
N3O3; C, 59.09; H, 6.61; Cl, 9.69; N, 11.49; O, 13.12; MS (ESI) 
m/z: 365.1506.
Synthesis of tert-butyl 1-(6-methoxybenzo[d]oxazol-2-yl)pip-
eridin-4-yl(methyl)carbamate 4
Compound 3 (10 mmol) was taken in methanol (100 mL) 
and allowed to solubilise, to this was added sodium meth-
oxide (15 mmol) and refluxed for 7 h. The mixture so ob-
tained was cooled to room temperature and excess of sol-
vent was removed under vacuo. The obtained residue was 
extracted with ethyl acetate and dried over sodium sul-
phate to obtain the white coloured amorphous product 4 
with 62 % yield. Mp: 292-294 ºC; 1H-NMR (CDCl3): δ 1.45 
(s, 9H, Boc-CH3), 1.62 (m, 2H, Piperidine-H), 1.88 (m, 2H, 
Piperidine-H), 2.2 (m, 2H, Piperidine-H), 2.4 (m, 2H, Piperi-
dine-H), 2.7 (s, 3H, N-CH3), 3.12 (s, 3H, OCH3), 3.79 (m, 2H, 
methylene-H), 7.21 (m, 1H, Ar-H), 7.80 (m, 1H, Ar-H); Anal. 
Calcd for C19H27N3O4; C, 63.14; H, 7.53; N, 11.63; O, 17.71; 
MS (ESI) m/z: 361.2.
Synthesis of 1-(6-methoxybenzo[d]oxazol-2-yl)-N-methylpip-
eridin-4-amine 5
Compound 4 (10 mmol) was taken in tetrahydrofuran (100 
mL) and mixed to form a uniform mixture, to this was add-
ed potassium iodide (10 mmol) and refluxed for 12 h. The 
mixture so obtained was cooled to room temperature and 
excess of solvent was removed under vacuo. The obtained 
residue was treated with trifluoroacetic acid in dichlo-
roethane to obtain deprotected amine5 with 71 % yield. Mp: 
167-169 ºC; 1H-NMR (CDCl3): δ 1.11 (m, 2H, Piperidine-H), 
1.34 (m, 2H, Piperidine-H), 2.1 (m, 2H, Piperidine-H), 
2.6 (m, 2H, Piperidine-H), 2.7 (s, 3H, N-CH3), 3.12 (s, 3H, 
OCH3), 3.79 (m, 2H, methylene-H), 7.25 (m, 1H, Ar-H), 7.88 
(m, 1H, Ar-H), 8.4 (s, 1H, NH); Anal. Calcd for C14H19N3O2; 
C, 64.35; H, 7.33; N, 16.08; O, 12.25; MS (ESI) m/z: 261.15.
General procedure for the synthesis of various N-substituted 
benzyl-1-(6-methoxybenzo[d]oxazol-2-yl)-N-methylpiperi-
din-4-amine 6a-l
In the last step compound 5 (0.2 mmol) was added to DMF 
(10 mL), to this solution anhydrous potassium carbonate 
(0.30 mmol) followed by various substituted benzyl chlo-
ride (0.2 mmol). This solution was stirred for 4 h at room 
temperature, on completion of reaction on the TLC water 
was added. The compound was extracted with DCM and 
dried over sodium sulphate, this was dried in vacuo to pro-
vide with final derivatives 6a-l.
N-Benzyl-1-(6-methoxybenzo[d]oxazol-2-yl)-N-methylpiperi-
din-4-amine 6a
59 % yield. Mp: 157-159 ºC; 1H-NMR (CDCl3): δ 1.43 (m, 
2H, Piperidine-H), 1.68 (m, 2H, Piperidine-H), 2.65 (s, 
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3H, N-CH3), 2.69 (m, 1H, Piperidine-H), 2.7 (m, 2H, Pip-
eridine-H), 2.8 (m, 2H, Piperidine-H), 3.62 (s, 2H, methyl-
ene-H), 3.73 (s, 3H, OCH3), 7.06 (m, 2H, Ar-H), 7.1 (m, 1H, 
Ar-H), 7.2 (m, 2H, Ar-H), 7.25 (m, 1H, Benzoxazolyl-H), 
7.88 (m, 2H, Benzoxazolyl-H); 13C NMR spectral data (25.15 
MHz, CDCl3): δ136.5 (C-2), 143.4 (C-4), 149.9 (C-5), 95.5 (C-
6), 158.3(C-7), 112.9(C-8), 119.7(C-9), 49.6(C-11), 31.8(C-12), 
51.3(C-13), 31.8(C-14), 49.6(C-15), 55.5(C-17), 42.7(C-19), 
57.5 (C-20), 136.7(C-21), 128.0 (C-22, C-26), 128.6(C-23,C-25), 
128.9 (C-24) Anal. Calcd for C21H25N3O2; C, 71.77; H, 7.17; N, 
11.96; O, 9.10; MS (ESI) m/z: 351.1947.
N - ( 4 - c h l o r o b e n z y l ) - 1 - ( 6 - m e t h o x y b e n z o [ d ] o x a z -
ol-2-yl)-N-methylpiperidin-4-amine6b
51 % yield. Mp: 151-153 ºC; 1H-NMR (CDCl3): δ 1.44 (m, 2H, 
Piperidine-H), 1.67 (m, 2H, Piperidine-H), 2.67 (s, 3H, N-CH3), 
2.68 (m, 1H, Piperidine-H), 2.75 (m, 2H, Piperidine-H), 2.82 
(m, 2H, Piperidine-H), 3.63 (s, 2H, methylene-H), 3.75 (s, 3H, 
OCH3), 7.08 (m, 2H, Ar-H), 7.29 (m, 2H, Ar-H), 7.42 (m, 1H, 
Benzoxazolyl-H), 7.88 (m, 2H, Benzoxazolyl-H); 13C NMR spec-
tral data (25.15 MHz, CDCl3): δ 136.5 (C-2), 143.4 (C-4), 149.2 
(C-5), 95.9 (C-6), 158.4(C-7), 112.4(C-8), 119.7(C-9), 49.3(C-
11), 31.5(C-12), 51.3(C-13), 31.8(C-14), 49.7(C-15), 55.7(C-
17), 42.4(C-19), 57.3 (C-20), 136.5(C-21), 129.6 (C-22, C-26), 
131.8(C-23,C-25), 124.2 (C-24) Anal. Calcd for C21H24ClN3O2; 
C, 65.36; H, 6.27; Cl, 9.19; N, 10.89; O, 8.29; MS (ESI) m/z: 
385.1557.
N - ( 4 - b r o m o b e n z y l ) - 1 - ( 6 - m e t h o x y b e n z o [ d ] o x a z -
ol-2-yl)-N-methylpiperidin-4-amine 6c
55 % yield. Mp: 154-156 ºC; 1H-NMR (CDCl3): δ 1.39 (m, 2H, 
Piperidine-H), 1.59 (m, 2H, Piperidine-H), 2.59 (s, 3H, N-CH3), 
2.68 (m, 1H, Piperidine-H), 2.75 (m, 2H, Piperidine-H), 2.82 
(m, 2H, Piperidine-H), 3.63 (s, 2H, methylene-H), 3.75 (s, 3H, 
OCH3), 7.11 (m, 2H, Ar-H), 7.30 (m, 2H, Ar-H), 7.42 (m, 1H, 
Benzoxazolyl-H), 7.88 (m, 2H, Benzoxazolyl-H); ); 13C NMR 
spectral data (25.15 MHz, CDCl3): δ 136.5 (C-2), 143.4 (C-4), 
149.2 (C-5), 95.9 (C-6), 158.4(C-7), 112.4(C-8), 119.7(C-9), 
49.3(C-11), 31.5(C-12), 51.3(C-13), 31.8(C-14), 49.7(C-15), 
55.7(C-17), 42.4(C-19), 57.3 (C-20), 136.5(C-21), 129.6 (C-
22, C-26), 131.8(C-23,C-25), 124.2 (C-24); Anal. Calcd for 
C21H24BrN3O2; C, 58.61; H, 5.62; Br, 18.57; N, 9.76; O, 7.44; MS 
(ESI) m/z: 429.1052
N - ( 4 - f l u o r o b e n z y l ) - 1 - ( 6 - m e t h o x y b e n z o [ d ] o x a z -
ol-2-yl)-N-methylpiperidin-4-amine 6d
61 % yield. Mp: 150-152 ºC; 1H-NMR (CDCl3): δ 1.43 (m, 2H, 
Piperidine-H), 1.66 (m, 2H, Piperidine-H), 2.67 (s, 3H, N-CH3), 
2.68 (m, 1H, Piperidine-H), 2.75 (m, 2H, Piperidine-H), 2.82 
(m, 2H, Piperidine-H), 3.63 (s, 2H, methylene-H), 3.75 (s, 3H, 
OCH3), 7.09 (m, 2H, Ar-H), 7.28 (m, 2H, Ar-H), 7.42 (m, 1H, 
Benzoxazolyl-H), 7.88 (m, 2H, Benzoxazolyl-H);13C NMR spec-
tral data (25.15 MHz, CDCl3): δ 136.1 (C-2), 143.9 (C-4), 149.3 
(C-5), 95.5 (C-6), 158.3(C-7), 112.6(C-8), 119.5(C-9), 49.4(C-
11), 31.4(C-12), 51.6(C-13), 31.5(C-14), 49.5(C-15), 55.5(C-
17), 42.1(C-19), 57.2 (C-20), 136.5(C-21), 129.8 (C-22, C-26), 
115(C-23,C-25), 163.4 (C-24);Anal. Calcd for C21H24FN3O2; 
C, 68.27; H, 6.55; F, 5.14; N, 11.37; O, 8.66; MS (ESI) m/z: 
369.1853.
N - (3 , 4 - dif luorobe nzyl) -1- (6 -methoxybe nzo[d]oxaz-
ol-2-yl)-N-methylpiperidin-4-amine 6e
65 % yield. Mp: 169-171 ºC; 1H-NMR (CDCl3): δ 1.44 (m, 2H, 
Piperidine-H), 1.67 (m, 2H, Piperidine-H), 2.67 (s, 3H, N-CH3), 
2.68 (m, 1H, Piperidine-H), 2.75 (m, 2H, Piperidine-H), 2.82 
(m, 2H, Piperidine-H), 3.63 (s, 2H, methylene-H), 3.75 (s, 3H, 
OCH3), 7.08 (m, 2H, Ar-H), 7.25 (m, 1H, Ar-H), 7.42 (m, 1H, 
Benzoxazolyl-H), 7.88 (m, 2H, Benzoxazolyl-H); 13C NMR spec-
tral data (25.15 MHz, CDCl3): δ 136.4 (C-2), 144.1 (C-4), 149.2 
(C-5), 95.2 (C-6), 158.9(C-7), 112.2(C-8), 119.7(C-9), 49.6(C-
11), 31.7C-12), 51.4(C-13), 31.8(C-14), 49.5(C-15), 55.9(C-
17), 42.3(C-19), 57.6 (C-20), 140.2(C-21), 129.8 (C-22, C-26), 
128.7(C-22), 133.2 (C-23), 133.6(C-24), 129.9, (C-25), 129.2 (C-
26); Anal. Calcd for C21H23F2N3O2; C, 65.10; H, 5.98; F, 9.81; N, 
10.85; O, 8.26; MS (ESI) m/z: 387.1758.
N - (4 - m e t h y lb e nz e n e) -1 - (6 - m e t h o x y b e nz o [d ] o x a z -
ol-2-yl)-N-methylpiperidin-4-amine 6f
61 % yield. Mp: 155-157 ºC; 1H-NMR (CDCl3): δ 0.9 (s, 3H, 
CH3), 1.42 (m, 2H, Piperidine-H), 1.66 (m, 2H, Piperidine-H), 
2.66 (s, 3H, N-CH3), 2.69 (m, 1H, Piperidine-H), 2.75 (m, 2H, 
Piperidine-H), 2.82 (m, 2H, Piperidine-H), 3.63 (s, 2H, methyl-
ene-H), 3.75 (s, 3H, OCH3), 7.18 (m, 2H, Ar-H), 7.29 (m, 2H, 
Ar-H), 7.42 (m, 1H, Benzoxazolyl-H), 7.88 (m, 2H, Benzoxa-
zolyl-H);13C NMR spectral data (25.15 MHz, CDCl3): δ 136.5 
(C-2), 143.7 (C-4), 149.4 (C-5), 95.9 (C-6), 158.4(C-7), 112.5(C-
8), 119.8(C-9), 49.1(C-11), 31.2(C-12), 51.9(C-13), 31.1(C-14), 
49.3(C-15), 55.2(C-17), 42.7(C-19), 57.4 (C-20), 136.5(C-21), 
128.2 (C-22, C-26), 125.1(C-23,C-25), 131.9 (C-24) , 124.1 (C-
27); Anal. Calcd for C22H27N3O2; C, 72.30; H, 7.45; N, 11.50; O, 
8.76; MS (ESI) m/z: 365.2103.
N-(4-(trif luoromethyl)benzyl)-1-(6-methoxybenzo[d]oxaz-
ol-2-yl)-N-methylpiperidin-4-amine6g
70 % yield. Mp: 148-150 ºC; 1H-NMR (CDCl3): δ 1.43 (m, 2H, 
Piperidine-H), 1.66 (m, 2H, Piperidine-H), 2.65 (s, 3H, N-CH3), 
2.69 (m, 1H, Piperidine-H), 2.74 (m, 2H, Piperidine-H), 2.82 
(m, 2H, Piperidine-H), 3.63 (s, 2H, methylene-H), 3.75 (s, 3H, 
OCH3), 7.18 (m, 2H, Ar-H), 7.29 (m, 2H, Ar-H), 7.42 (m, 1H, 
Benzoxazolyl-H), 7.88 (m, 2H, Benzoxazolyl-H); 13C NMR spec-
tral data (25.15 MHz, CDCl3): δ 136.2 (C-2), 143.5 (C-4), 149.1 
(C-5), 95.2 (C-6), 158.7(C-7), 112.3(C-8), 119.4(C-9), 49.3(C-
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11), 31.4(C-12), 51.7(C-13), 31.5(C-14), 49.4(C-15), 55.3(C-
17), 42.2(C-19), 57.6 (C-20), 136.7(C-21), 128.5 (C-22, C-26), 
128.3(C-23,C-25), 139.8 (C-24) , 21.3 (C-27); Anal. Calcd for 
C22H24F3N3O2; C, 63.00; H, 5.77; F, 13.59; N, 10.02; O, 7.63; MS 
(ESI) m/z: 419.1821.
N - (4 - t e r t - but ylbe nzyl) -1- (6 -methox ybe nzo[d]oxaz-
ol-2-yl)-N-methylpiperidin-4-amine6h
65 % yield. Mp: 168-170 ºC; 1H-NMR (CDCl3): δ 1.33 (s, 9H, 
CH3), 1.43 (m, 2H, Piperidine-H), 1.66 (m, 2H, Piperidine-H), 
2.65 (s, 3H, N-CH3), 2.69 (m, 1H, Piperidine-H), 2.74 (m, 2H, 
Piperidine-H), 2.82 (m, 2H, Piperidine-H), 3.63 (s, 2H, methyl-
ene-H), 3.75 (s, 3H, OCH3), 7.18 (m, 2H, Ar-H), 7.29 (m, 2H, 
Ar-H), 7.42 (m, 1H, Benzoxazolyl-H), 7.88 (m, 2H, Benzoxa-
zolyl-H);13C NMR spectral data (25.15 MHz, CDCl3): δ 136.5 
(C-2), 143.3 (C-4), 149.8 (C-5), 95.3 (C-6), 158.3(C-7), 112.6(C-
8), 119.2(C-9), 49.5(C-11), 31.5(C-12), 51.2(C-13), 31.5(C-14), 
49.2(C-15), 55.8(C-17), 42.3(C-19), 57.7 (C-20), 136.8(C-21), 
128.1 (C-22, C-26), 129.4(C-23,C-25), 144.5 (C-24) , 35.1 
(C-27), 33.5(C-28), 29.1(C-29), 14.0(C-30); Anal. Calcd for 
C25H33N3O2; C, 73.68; H, 8.16; N, 10.31; O, 7.85; MS (ESI) m/z: 
407.2573.
N-(4-nitrobenzyl)-1-(6-methoxybenzo[d]oxazol-2-yl)-N-meth-
ylpiperidin-4-amine 6i
70 % yield. Mp: 177-179 ºC; 1H-NMR (CDCl3): δ 1.43 (m, 2H, 
Piperidine-H), 1.66 (m, 2H, Piperidine-H), 2.65 (s, 3H, N-CH3), 
2.69 (m, 1H, Piperidine-H), 2.74 (m, 2H, Piperidine-H), 2.82 
(m, 2H, Piperidine-H), 3.63 (s, 2H, methylene-H), 3.75 (s, 3H, 
OCH3), 7.18 (m, 2H, Ar-H), 7.29 (m, 2H, Ar-H), 7.42 (m, 1H, 
Benzoxazolyl-H), 7.88 (m, 2H, Benzoxazolyl-H);13C NMR spec-
tral data (25.15 MHz, CDCl3): δ 136.3 (C-2), 143.7 (C-4), 149.3 
(C-5), 95.5 (C-6), 158.4(C-7), 112.7(C-8), 119.3(C-9), 49.5(C-
11), 31.6(C-12), 51.8(C-13), 31.3(C-14), 49.4(C-15), 55.3(C-
17), 42.9(C-19), 57.5(C-20), 136.7(C-21), 127.9 (C-22, C-26), 
117.3(C-23,C-25), 140.5 (C-24) Anal. Calcd for C21H24N4O4; C, 
63.62; H, 6.10; N, 14.13; O, 16.14; MS (ESI) m/z: 396.1798.
N - (2 , 5 - dimethylbenzyl) -1- (6 -methoxybenzo[d]oxaz-
ol-2-yl)-N-methylpiperidin-4-amine6j
55 % yield. Mp: 154-156 ºC; 1H-NMR (CDCl3): 1H-NMR 
(CDCl3): δ 1.43 (m, 2H, Piperidine-H), 1.66 (m, 2H, Pip-
eridine-H), 2.35 (s, 6H, CH3), 2.65 (s, 3H, N-CH3), 2.69 (m, 
1H, Piperidine-H), 2.74 (m, 2H, Piperidine-H), 2.82 (m, 
2H, Piperidine-H), 3.63 (s, 2H, methylene-H), 3.75 (s, 3H, 
OCH3), 7.18 (m, 2H, Ar-H), 7.29 (m, 1H, Ar-H), 7.42 (m, 1H, 
Benzoxazolyl-H), 7.88 (m, 2H, Benzoxazolyl-H);13C NMR 
spectral data (25.15 MHz, CDCl3): δ 136.6 (C-2), 143.8 (C-
4), 149.2 (C-5), 95.4 (C-6), 158.5(C-7), 112.2(C-8), 119.8(C-9), 
49.2(C-11), 31.3(C-12), 51.2(C-13), 31.6(C-14), 49.4(C-15), 
55.2(C-17), 42.7(C-19), 53.7(C-20), 131.3(C-21), 129.2 (C-22), 
127.8(C-26), 129.1(C-23),128.6(C-25), 139.4 (C-24), 18.7(C-
25), 20.9(C-26); Anal. Calcd for C23H29N3O2; C, 72.79; H, 
7.70; N, 11.07; O, 8.43; MS (ESI) m/z: 379.226.
N-(2, 5 -dimethoxybenzyl) -1- (6 -methoxybenzo[d]oxaz-
ol-2-yl)-N-methylpiperidin-4-amine 6k
67 % yield. Mp: 162-164 ºC; 1H-NMR (CDCl3): 1H-NMR 
(CDCl3): δ 1.42 (m, 2H, Piperidine-H), 1.64 (m, 2H, Piperi-
dine-H), 2.64 (s, 3H, N-CH3), 2.69 (m, 1H, Piperidine-H), 
2.73 (m, 2H, Piperidine-H), 2.83 (m, 2H, Piperidine-H), 
3.63 (s, 2H, methylene-H), 3.72 (s, 6H, OCH3), 3.80 (s, 3H, 
OCH3), 7.18 (m, 2H, Ar-H), 7.29 (m, 1H, Ar-H), 7.42 (m, 1H, 
Benzoxazolyl-H), 7.89 (m, 2H, Benzoxazolyl-H);13C NMR 
spectral data (25.15 MHz, CDCl3): δ 136.7 (C-2), 143.5 (C-
4), 149.8 (C-5), 95.1 (C-6), 158.2(C-7), 112.7(C-8), 119.5(C-9), 
49.3(C-11), 31.9(C-12), 51.4(C-13), 31.3(C-14), 49.3(C-15), 
55.4(C-17), 42.2(C-19), 53.7(C-20), 127.7(C-21), 158.1 (C-22), 
111.2(C-26), 112.3(C-23),157.7(C-25), 115.3 (C-24), 55.9(C-
28), 55.5(C-30); Anal. Calcd for C23H29N3O4; C, 67.13; H, 
7.10; N, 10.21; O, 15.55; MS (ESI) m/z: 411.2158.
N-(3,4,5-trimethoxybenzyl)-1-(6 -methoxybenzo[d]oxaz-
ol-2-yl)-N-methylpiperidin-4-amine6l
72 % yield. Mp: 169-171 ºC; 1H-NMR (CDCl3): 1H-NMR 
(CDCl3): δ 1.41 (m, 2H, Pieridine-H), 1.63 (m, 2H, Piperi-
dine-H), 2.65 (s, 3H, N-CH3), 2.68 (m, 1H, Piperidine-H), 
2.73 (m, 2H, Piperidine-H), 2.84 (m, 2H, Piperidine-H), 3.61 
(s, 2H, methylene-H), 3.75 (s, 9H, OCH3), 3.80 (s, 3H, OCH3), 
7.19 (m, 1H, Ar-H), 7.27 (m, 1H, Ar-H), 7.41 (m, 1H, Benzox-
azolyl-H), 7.90 (m, 2H, Benzoxazolyl-H);13C NMR spectral 
data (25.15 MHz, CDCl3): δ 136.6 (C-2), 143.8 (C-4), 149.2 
(C-5), 954 (C-6), 158.5(C-7), 112.2(C-8), 119.8(C-9), 49.2(C-
11), 31.3(C-12), 51.2(C-13), 31.6(C-14), 49.4(C-15), 55.2(C-
17), 42.7(C-19), 53.7(C-20), 142.7(C-21), 107.6 (C-22, C-26), 
152.9(C-23,C-25),139.2 (C-24), 56.2(C-28, C32), 60.9(C-30); 
Anal. Calcd for C24H31N3O5; C, 65.29; H, 7.08; N, 9.52; O, 
18.12; MS (ESI) m/z: 441.2264.
Molecular modelling and docking studies
Active site determination for Hsp70 and Hsp90
All the molecular modelling studies were carried out on the 
Schrodinger modelling suite (Version 15.3). The Heat Shock 
Proteins (Hsp) 70 and 90 were obtained from Brookhaven 
Protein Data Bank (RCSB-PDB). Initially the proteins crys-
tals obtained from PDB were analysed and the active sites 
were determined. Hsp70 (PDB Id: 2XA4) and Hsp90 (PDB 
Id: 3FGR) were prepared in the protein preparation wiz-
ard of the Schrodinger suite for knocking out the bound 
ligands and cofactors, excess and nonessential water mole-
cules were also removed. The proteins were optimised and 
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missing loops were filled and overlapping residues were 
corrected, finally both the target proteins were optimised 
for their conformational energies. These were further sub-
jected to Q-site program to determine the active sites with-
in the protein strucutre.14 The active sites were determined 
with regions such as hydrophobic and polar-regions as pre-
sented in figure 2.
Molecular docking studies
The compounds designed were subjected to energy mini-
misation by Ligprep module of the software. Glide module 
was employed for the molecular docking; compounds were 
docked in the grid designed in the module. The docking 
was carried out with flexible ligands and the protein with 
the simulations made on the OPLS5.0 force field. All the 
results were based on 10 conformations for each molecule 
in the standard precision (SP) mode. The crystal structure 
Hsp70 (PDB Id: 2XA4) and Hsp90 (PDB Id: 3FGR) were both 
employed as the receptor with compounds 6a-l as ligands.14 
The results obtained from the simulation were obtained in 
the form of dock score and Glide energy, these values rep-
resents the minimum energies. Interactions between the li-
gand and residues were presented in the form of H-bond, 
van der Waals forces and the pi bonds. The results in the 
form of 3D and 2D representation were obtained for sim-
plified understanding and presented as figure 2 and Fig 3
Figure 2: a) Active site determination in the Hsp70 (PDB Id: 2XA4); b) Active site determination in the Hsp90 (PDB Id: 3FGR) 
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Figure 3: Molecular docking study on compounds from the series; a,b) 3D and 2D representation of compound 6bonHsp70  
(PDB Id: 2XA4); c,d) 3D and 2D representation of compound 6ion Hsp70 (PDB Id: 2XA4).
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IC50 for both the compounds are explained in figure 4A for 6band 6i. 
Figure 4. A) Molecular docking study on compounds from the series; a, b) 3D and 2D representation of compound 6b onHsp90 (PDB Id: 
3FGR); c, d) 3D and 2D representation of compound 6i on Hsp90 (PDB Id: 3FGR). B) Compound 6b and 6i inhibited overall cell viability 
(% relative to control) DU-145 and 22Rv1 (Cell lines for Prostate cancer). The cell viability was determined by plotting CCK-8 assay with 
increasing concentration of compoundsfor 24 hours.
Table 1: Antitumor activity of some novel hybrids of benzoxazole,the table represents concentration as a result of 50% loss of viable 
cells with respect to untreated cells (IC50). The results were defined from dose-response curves for two different cell lines DU-145 and 
22Rv1. It also presents the glide score and energies for different derivatives in front respective derivatives.
Sr. no. Compd no.
IC50 (µM) Dock score
DU145 22Rv1
Hsp 70 Hsp 90
Dock Score GlideEnergy
Dock
Score
Glide
Energy
1 6a 28.91 27.51 -8.0251 -46.3115 -5.07476 -34.435
2 6b 20.10 19.41 -8.12051 -46.1657 -5.08201 -49.2727
3 6c >100 48.12 -7.76383 -48.4989 -4.41685 -43.5636
4 6d 47.45 44.94 -7.91281 -46.2466 -5.09304 -39.2727
5 6e 29.35 45.21 -8.02916 -49.2831 -5.34989 -46.6876
6 6f >100 43.33 -8.02665 -46.5599 -3.7217 -35.7962
7 6g 45.24 35.55 -7.85481 -48.8817 -3.39334 -35.8336
8 6h 41.42 39.92 -7.51404 -46.4911 -3.51714 -38.4987
9 6i 20.5 19.00 -8.84901 -49.7121 -5.34706 -46.6326
10 6j >100 43.36 -7.70333 -45.1409 -4.43773 -32.1075
11 6k >100 44.33 -7.32014 -46.7713 -4.98797 -37.4438
12 6l 47.10 44.89 -7.63666 -49.3863 -3.6077 -39.2424
13 StdEnzalutamide 28.22 31.72 -7.344 -46.7819 -5.09304 -39.2727
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In vitro screening 
Cell Culture
The cell lines DU-145 and 22Rv1 were obtained from the 
ATCC, USA; DU145, 22Rv1 and RWPE-1 werepreserved 
at -80 ºC according to the standard protocol. These were 
further cultured in Dulbecco’s Eagle medium modified and 
supplemented, it contains fetal Bovine Serum (10%) along 
with penicillin-100 U/mL and streptomycin-0.1 mg/mL as 
per the requirement. Before use these cell lines were kept 
for incubation at 37 ºC with controlled humidity and 5 % 
carbon dioxide. 
Oncotest assay method for anitproliferative activity15,16
Oncotest’s monolayer assay was developed for testing the 
antiproliferative activity of newly developed compounds 
was found to the most accurate and suitable method for 
evaluation of these compounds. This method was found to 
be highly accurate and specific for testing of compounds on 
prostate cancer cell lines. The widely used anticancer drug 
enzalutamide was used as standard drug on both the cell 
lines along with other test compounds. This assay is based 
on the propedium iodide method, the test compounds are 
observed after four days of treatment. All the derivative 
6a-l were tested for ten dilutions with half log increasing 
to the 100 1M. The readings were taken in triplicates and 
observations were presented by nonlinear regression anal-
ysis as IC50 in table 1 forming the results. The detailed ex-
perimental protocol is provided with the supplementary 
material available online.
Antitumor Activity by CCK-8 Assay17
The CCK-8 assay stands for Cell Counting Kit 8 (CCK 8) 
which was developed by Dojindo Corporation in Japan. It 
is a ready to use kit to determine the extent of prolifera-
tion by both cell lines DU-145 and 22Rv1 the selected com-
pounds 6b and 6i. (Figure-4B).Three replicates for each of 
the compound was carried out and the cell growth inhibi-
tion was calculated as the following formula;
Surface Plasmon Resonance (SPR) Analysis18
All the SPR readings were obtained from optical biosen-
sor Biacore T100 (GE Company) reported elsewhere. The 
human HSP70 (ADI-ESP-550-F [200 µg], Enzo Life Scienc-
es)was immobilized on a CM5 sensor chip (GE) using 10 
mmol/PBS at pH 5.0. The binding experiments were car-
ried out at 25 ºC using a flow rate of 30 mL/L at 90 s of 
monitoring for association and 120 s of monitoring fordis-
sociation of the ligand and substrate. All studies were per-
formed witheight dilutions as 0.003, 0.01, 0.03, 0.1, 0.3, 1, 3, 
and10 mM, with all of these prepared with 5% DMSO in 
PBS along with it 5% DMSO in PBS was used as a running 
buffer andblank control. The datawasdelivered using equi-
librium dissociation constant (Kdvalue). This was calculat-
ed following equation as:
Response = Conc x Rmax / [conc + Kd] + offset
Table 2: The inhibitor binding of Heat Shock Protein 70 (Hsp70) 
by kinetic characterisation*
Sr. No. Name Kd (mol/L)
1 6b 2.030 x 10-6
2 6i 2.421 x 10-6
3 Std 2.066 x 10-6
* Determination of kinetic rate constants and affinities.
RESULTS AND DISCUSSION
Prostate cancer has been treated with the help of chemother-
apy and surgery, but rise in incidences of drug resistance 
in prostate carcinoma have inclined the treatment more to-
wards surgery. This lead to need for newer and better drug 
molecules to treat the disease and hence forth discovery of 
newer targets. Hsp70 and Hsp90 has been studied for their 
role in the prostate carcinoma, it was found that there is an 
elevation and elevated expression of these proteins in the 
patients suffering from cancer. Further it was established 
that upregulation of these to heat shock proteins plays a 
significant role in cancer progression and hence are good 
targets for treatment of prostate cancer. Herein we have de-
scribe design and development of few novel inhibitors of 
Hsp70 and Hsp90 for their application towards treatment 
of prostate cancer. The design of new molecules is based 
on the structural features like the fused aromatic nucleus, 
cyclic aliphatic group and halogen substitutions on the 
aromatic ring. These features are found to me common in 
many anticancer agents with use in treatment of prostate 
cancer. On the basis of hybrid approach we designed a se-
ries of derivatives with a fused aromatic nucleus the ben-
zoxazole, cyclic aliphatic group the piperidine linker and 
aromatic ring with various substitutions. 
The synthesis was carried out in four steps, first step in-
volved substitution of piperidine ring 2 on the 2-chloro 
benzoxazole 1 leading to formation of the tert-butyl 
1-(6-chlorobenzo[d]oxazol-2-yl)piperidin-4-yl(methyl)car-
bamate 3, this was furthertreated with sodium methoxide 
in methanol to obtain tert-butyl 1-(6-methoxybenzo[d]oxa-
zol-2-yl)piperidin-4-yl(methyl) carbamate 4. This was de-
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protected by removing Boc to yield1-(6-methoxybenzo[d]
oxazol-2-yl)-N-methylpiperidin-4-amine 5. In the final step 
various phenyl chlorides were substituted to yield corre-
sponding derivatives as N-substituted benzyl-1-(6-meth-
oxybenzo[d]oxazol-2-yl)-N-methylpiperidin-4-amine 6a-l. 
These compounds were characterisedfor their structural 
confirmation and molecular structures were established.
To study the biological efficacy of these compounds on-
cotest assay method was performed on two cell lines DU145 
and 22Rv1. The results obtained from this assay shows that 
two compounds 6b and 6i have good IC50 values (Table 1). 
Compound 6b had IC50 of 20.10 and 19.41 for the DU145 
and 22Rv1 respectively, while 6i had IC50 of 20.5 and 19.00 
for DU145 and 22Rv1 respectively, this is quit satisfactory 
compared to the standard drug enzalutamide. In the subse-
quentevaluation these compounds were studied on the ba-
sis of CCK-8 assay for the two cell lines DU145 and 22Rv1 
and cell viability was studied. It was found that compound 
6i inhibits the 22Rv1 more efficiently ten Du145 whereas 6b 
has more inhibitory activity on the 22Rv1 (Fig 5). In order to 
understand the mechanism of action of these two molecules 
molecular docking studies were carried out. Two different 
receptors were obtained from the protein data bank, Hsp70 
(PDB ID: 2XA4) and Hsp90 (PDB ID: 3FGR). Initially these 
two proteins were subjected to protein preparation leading 
to filling of missing loops and resolving the overlapping 
residues. After optimising these protein on the Schrodinger 
protein preparation wizard these were subjected to Qsite 
finder. Qsite determines the active site within the receptor 
which is important for determining the residues involved 
in interaction with the ligands (Figure 2). In case of Hsp70 
it was found that residues Leu40, Val186, Asp93, Trp162, 
Phe138, Ser52, Leu103, Asn51 and Gly100 form the active 
site and consist of an cavity within the receptor. In Hsp90 
the active site was formed of Ser342, Phe235, Ile345, Lys273, 
Ser277, Arg274, Ser278, Glu233 and Arg344. 
The molecular docking was carried out for the two com-
pounds 6b and 6i in these active sites of Hsp70 and Hsp90 
with the help of Glide module of Schrodinger software 
version 9.5. The compounds were docked on both the re-
ceptors and scores were obtained for their binding glide 
energy and dock score. The results are shown in table 1, it 
can be seen that both compounds have performed well in 
the docking studies. Compound 6b has good dock score of 
-8.12 and Glide score of -46.16 for Hsp70, for Hsp90 it had 
dock score of -5.08 and Glide energy of -49.27. Compound 
6i has good dock score of -8.84 and Glide score of -49.71 for 
Hsp70, for Hsp90 it had dock score of -5.34 and Glide ener-
gy of -46.63. Figure 3 shows the tree dimensional and two 
dimensional images of the compounds 6b and 6i interact-
ing with Hsp70. It is clearly observed that the compound6b 
forms hydrogen bond with the amine group of the linker 
and Asp93, two pi bond interactions are observed between 
the Phe138 and Trp162 with the benzoxazole nucleus. 
Compound 6iinteracts with the receptor forming hydrogen 
bonds with Asn51 and Asp93, pi bond between Phe138 and 
Trp162, hydrogen and salt bridge with the Lys58. Figure 4 
shows the tree dimensional and two dimensional images 
of the compounds 6b and 6i interacting with Hsp970. It is 
observed that 6b forms an hydrogen bond with Ser342 and 
6i forms an pi bond with the Arg344 These results suggest 
that compound 6b and 6i have high affinity for the Hsp70 
compared to Hsp90. 
In order to further investigate the efficacy of compound 6b 
and 6i we carried out the drug binding assay based on the 
surface plasmone resonance (SPR) principle on the Hsp70. 
The experiment was carried out on the human Hsp70 and 
the association and disassociation of the ligand with the 
substrate was determined (Table 2). The dissociation con-
stant (Kd) was calculated and it was found that compound 
6b had Kd = 2.030 x 10-6and 6i had Kd = 2.421x 10-6compared 
to the standard with Kd = 2.066 x 10-6. This indicates that 
compound 6b and 6i are having comparable affinity to-
wards the Hsp90. 
CONCLUSION
Present study provides with two novel molecules 6b and 
6i, these have good inhibitory activity against the Hsp70 
and Hsp90, but it is more specific for the inhibition of the 
Hsp70. The results obtained and the observation make it 
clear that these compounds have good in vitro activity 
against prostate cancer. These compounds can be further 
evaluated for their in vivo activity against the prostate can-
cer and developed into lead molecules. 
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